Search
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia
Categories: Compounds used in a research, industrial, or household settingCamptothecin
go.drugbank.com/drugs/DB04690InvestigationalThis compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Synonyms: D-camptothecinVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated … [A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis and thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigationalTeplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D). … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalMost recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881] … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalIn addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … PLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]
Phenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during
Echinomycin
go.drugbank.com/drugs/DB15582ExperimentalEchinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.
Synonyms: Quinomycin A